Celgene signs $1.5bn deal with Immatics for ‘key’ to treat solid tumors
Celgene agrees option to acquire rights to three TCR-T therapies from Immatics, with the aim of developing potential treatments for solid tumors.
Celgene agrees option to acquire rights to three TCR-T therapies from Immatics, with the aim of developing potential treatments for solid tumors.
Alligator grants Biotheus rights to an antibody for the creation of three bispecific molecules in the Greater China region.
UK government invests further in businesses manufacturing advanced therapies, opening a fund for companies working on technology to improve commercial production.